Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
Medicinal packaging doesn’t have to be harsh and strident. That’s the concept behind the biosimilar packaging for which Samsung Bioepis continues to earn international awards. Most recently, Samsung Bioepis has garnered International Forum (iF) Design Award 2021 honors for packaging.
Soft shapes and soothing mono-colors characterize the package designs for Samsung Bioepis’ drug products, which include biosimilars. The company, based in Incheon, Republic of Korea, has called its package design concept “Passion for Health—Pure Joy in Life.”
“Taking medication can be a constant reminder of the medical condition, and we wanted to remind patients of ‘pure joy’ in life when they look at our product packaging and design,” Jaywoo Kim, senior vice president and manufacturing division leader at Samsung Bioepis, said in a statement.
The company won in 2 categories: Packaging—Medicine/Pharmaceutics and Communication—Corporate Identity/Branding.
In 2020, the company won package design awards in the Red Dot competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.